ea0098t4 | Trials In Progress | NANETS2023
Iyer, MD Gopa
, Demeure, MD Michael J.
, Ding, MS, MA Li
, Schmid, PhD Anita N.
, Navarro, MD Willis
, Kwiatkowski, MD, PhD David J.
, Rodon Ahnert, MD, PhD Jordi
Background: nab-Sirolimus, approved in the US for patients with advanced malignant PEComa, is a novel albumin-bound mTOR inhibitor (mTORi) that inhibits the mTOR pathway via suppression of the mTORC1 complex. When TSC1 or TSC2 is inactivated via mutation or loss, the mTOR pathway may be aberrantly activated. TSC1 and TSC2 alterations occur in a range of common cancers. Clinically, in the AMPECT exploratory analysis of nab-sirolimus in advanced malignant PEComa (NCT02494570), 8...